Let there be LIGHT! 💡 Memorial Sloan Kettering Cancer Center scientists including Dr. Winson Cai developed CAR T cells that overexpress LIGHT, a ligand of both LTβR on cancer cells and HVEM on immune cells, to overcome antigen heterogeneity. bit.ly/4ePSYZi

aacrjournals.org/cancerimmunolr…

U can butterfly your chicken drummies I was today years old.

Ok so I think at least two of these are pranks on tourists

This guy just fulfilled everyone's childhood dream 🤩

Cytokine-mediated CAR T therapy resistance in AML pubmed.ncbi.nlm.nih.gov/39333315/

shoshin Future AML therapeutic landscape will be less about ORR or CR, and more about MRD negativity, DOR and OS… nonetheless path forward for AFM28 could involve allo NK combo, or other chemo/HMA combos depending on population, still intriguing initial #AFM28 monotherapy activity $AFMD

3- #AML #ALL #CARTRX #RNP ash.confex.com/ash/2024/webpr…

5- #AML #CARTRX #CD371 ash.confex.com/ash/2024/webpr…

#ASH24: Join leukemia specialist Dr. Mark Blain Geyer for his poster session on "CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion & Disease Clearance in Patients with Refractory Acute Myeloid Leukemia" today at ASH. bit.ly/4gosP3F

Development incoming🔬 Our first URM Program grantee, Jennifer Lewis, has co-authored an abstract with Takeshi Fujino, from Memorial Sloan Kettering Cancer Center, on a CAR-T product that shows early promise in treating #AML. #ASH24 @LLSResearch

Impromptu class of 2016 MSKCC reunion! #ASH24

This is the table we’ve used (indication, common AEs, and black📦warnings) for approved #CART THERAPY w/ Jason Westin, MD FACP FASCO & Surbhi Sidana, MD #AxiCel #BrexuCel #LisoCel #TisaCel #IdeCel #CiltaCel #mmsm #OncTwitter #lymsm #MedTwitter OncoAlert #HemeTwitter #ASH24

Happy to share our new study in Nature Biomedical Engineering describing our “Zip-sort” strategy to purify dual-transduced cells with larger transgene payloads. Thanks to all our collaborators. @Parkerici @Cityofhope Memorial Sloan Kettering Cancer Center @Bushmanlab Vardhana Lab Klebanoff_Lab rdcu.be/d4y28. 1/

Very nice Fred Hutch Cancer Center presentation by #noamkopmar at Journal Watch about obe-cel versus brexu-cel as a CD19 CAR-T product in B-ALL. Love this graphic, including icon for a patient rebuilding their life after CAR-T! Cc Mazyar Shadman, MD MPH Folashade Otegbeye Jordan Gauthier Andrew Portuguese Ryan Cassaday

Despite efforts to understand, we still do not know how to use it. A survey-review of the current landscape of immune monitoring procedures in CAR-T cell therapies across EBMT-affiliated centers. 👇EBMT_Cellular_Therapy Annalisa Ruggeri Jurgen Kuball Christian Chabannon sciencedirect.com/science/articl…

I am very excited to share our latest work which is now out in JCI! We developed a transgenic mouse model to study the cooperativity of Trp53 and Tet2 LOF co-mutations in driving leukemic transformation with immune suppressive microenvironment. The mouse model phenocopies AML

Excited to announce a new paper in Cancer Discovery with Junwei Shi, Zhendong (Tom) Cao, Anthony Daniyan and led by Pu Zhang. We perform screens of GAPs and GEFs in AML and discover a hematopoietic-specific GAP (ARHGAP45) required in AML: aacrjournals.org/cancerdiscover…

Congratulations to Anthony Daniyan & team from Memorial Sloan Kettering Cancer Center on publication of the initial data from AML patients treated with IL-18 secreting CD371 CAR T cells @MSK. ashpublications.org/blood/article-… 3 / 5 patients experienced MRD-negative morphologic leukemia free state.

Results of a pilot study led by investigators at Memorial Sloan Kettering Cancer Center showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. Blood Journals Portfolio Anthony Daniyan Abdel-Wahab Lab Learn more: